<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>20 elderly patients with average age of 64 +/- 0.1, who had had their atherosclerotic <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> within the period from one month till one year, have taken Simvatin for two months in the dose of 10 mg. per day </plain></SENT>
<SENT sid="1" pm="."><plain>Analysis of the central hemodynamics and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism before and after the treatment with Simvatin showed that the medication improves central hemodynamics (linear systolic velocity in common carotid and vertebral arteries increases and peripheral resistance in complicated internal carotid artery and two vertebral arteries decreases, dimension of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> plaques and intima-media of common carotid artery decrease </plain></SENT>
<SENT sid="2" pm="."><plain>Simvatin lowers the content of <z:chebi fb="0" ids="16113">cholesterin</z:chebi>, <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> and fibrinogens </plain></SENT>
<SENT sid="3" pm="."><plain>Positive effect of treatment with Simvatin on the cerebral hemodynamics, intensity of atherosclerotic process and <z:chebi fb="23" ids="18059">lipid</z:chebi> methabolism proves the medication to be recommended in treatment of patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in anamnesis </plain></SENT>
</text></document>